Research Paper Volume 10, Issue 11 pp 3294—3307

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts

Figure 4. BrdU-treatment of MRC-5 cells effectively inhibits DNA-synthesis and induces Beta-Galactosidase. Two-day treatment with BrdU significantly reduced DNA synthesis in MRC-5 fibroblasts by ~70%, as measured with the Muse cell cycle kit. MRC-5 cells after 8 days of BrdU treatment were positively stained for Beta-Galactosidase. n=3; * p < 0.05.